Tecentriq - Google Patents
Tecentriq® rTecentriq
View PDF- Document ID
- 9955667007602133085
- Author
- Tecentriq P
External Links
Snippet
One 14 mL vial of concentrate contains 840 mg of atezolizumab. After dilution, the final concentration of the diluted solution should be between 3.2 and 16.8 mg/mL. For dilution and other handling recommendations, see section 2.3. For the full list of excipients, see …
- 229940066453 Tecentriq 0 title description 418
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019261666B2 (en) | Uses for and article of manufacture including HER2 dimerization inhibitor Pertuzumab | |
| US20240026003A1 (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| US20180078496A1 (en) | Article of manufacture comprising aflibercept or ziv-aflibercept | |
| WO2015088847A1 (en) | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor | |
| Udagawa et al. | Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer | |
| KR20230030621A (en) | Pertuzumab + Trastuzumab Fixed Dose Combination | |
| WO2021143799A1 (en) | Use of anti-pd-1 antibody in combination with fruquintinib in preparation of medicaments for treating cancer | |
| JP2021501150A (en) | Compositions and Methods for Treating Liver Cancer | |
| Tecentriq | Tecentriq® r | |
| US10766961B2 (en) | Anti-VEGFR2 antibody therapy for hepatocellular carcinoma | |
| Lu et al. | Efficacy and safety of anti–programmed death-ligand 1 monoclonal antibody socazolimab with carboplatin and Etoposide for extensive-stage SCLC: results from the phase 1b clinical trial | |
| CN113117072A (en) | Pharmaceutical composition of quinoline derivative and PD-1 monoclonal antibody | |
| CA3167799A1 (en) | Combined use of pertuzumab, trastuzumab, and anthracycline-based chemotherapy for neoadjuvant therapy of early-stage her2-positive breast cancer | |
| EP4427751A1 (en) | Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma | |
| Dai et al. | Capecitabine and Oxaliplatin (CAPEOX) combined with Sintilimab plus bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or esophagogastric junction adenocarcinoma: study protocol of a single-arm, phase Ib/II trial | |
| Rugo et al. | Highlights in Metastatic Breast Cancer From the 2020 San Antonio Breast Cancer Symposium | |
| US20240368310A1 (en) | Use of approved bispecific egfr and met specific antibody drug product to treat non-small cell lung cancer | |
| Bardia | Highlights in Metastatic Breast Cancer From the European Society for Medical Oncology Virtual Congress 2020 | |
| TW202228772A (en) | Pancreatic cancer quadruplet therapeutic agent combining atezolizumab, tocilizumab, gemcitabine, and nab-paclitaxel | |
| CN114432438A (en) | Pharmaceutical composition of quinoline derivative and PD-1 monoclonal antibody | |
| Ying | Efficacy and safety of sintilimab and anlotinib in combination with gemcitabine plus cisplatin as first-line therapy in patients with advanced biliary tract cancer: a randomized, open-label, multicentre, phase 2 SAGC study | |
| Gandara et al. | A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta®) and Erlotinib (Tarceva®) vs Single Agent Pemetrexed (Alimta®) in Patients with Progressive or Recurrent Non-Small Cell Lung Cancer (NSCLC) | |
| None | Product Fact Sheet for OPDIVO®(nivolumab) | |
| Dahlberg et al. | A Phase 2 Study of Durvalumab in Combination with Tremelimumab in Malignant Pleural Mesothelioma Coordinating Center: Dana-Farber Cancer Institute | |
| des Moulins | PROTOCOL NUMBER: MEDI4736-NHL-001 ORIGINAL DATE: 06 Nov 2015 AMENDMENT No. 1 DATE: 04 May 2017 AMENDMENT No. 2 DATE: 14 Dec 2017 AMENDMENT No. 3 DATE: 12 Sep 2019 |